Glenmede Trust’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.6M Buy
48,182
+1,654
+4% +$613K 0.08% 208
2026
Q1
$13.6M Buy
46,528
+7,234
+18% +$2.38M 0.07% 252
2025
Q4
$13.8M Buy
+39,294
New +$13.3M 0.07% 260
2025
Q1
$13.3M Sell
30,464
-30,061
-50% -$12.1M 0.07% 280
2024
Q4
$22.3M Sell
60,525
-30,175
-33% -$12.6M 0.11% 168
2024
Q3
$47.2M Sell
90,700
-36,028
-28% -$19.2M 0.23% 94
2024
Q2
$68.7M Sell
126,728
-8,125
-6% -$4.29M 0.35% 72
2024
Q1
$69.9M Sell
134,853
-24,851
-16% -$12.4M 0.35% 70
2023
Q4
$75.3M Buy
159,704
+16,475
+12% +$7.62M 0.39% 60
2023
Q3
$62.4M Sell
143,229
-2,040
-1% -$925K 0.36% 71
2023
Q2
$66.8M Sell
145,269
-66
-0% -$30.4K 0.38% 71
2023
Q1
$66.8M Buy
145,335
+3,221
+2% +$1.53M 0.38% 71
2022
Q4
$72.9M Sell
142,114
-5,945
-4% -$3.02M 0.43% 61
2022
Q3
$67.3M Buy
148,059
+75,150
+103% +$36M 0.42% 59
2022
Q2
$35.2M Buy
72,909
+1,140
+2% +$564K 0.21% 112
2022
Q1
$35.3M Buy
71,769
+7,776
+12% +$3.55M 0.17% 138
2021
Q4
$29.7M Buy
63,993
+5,224
+9% +$2.2M 0.14% 167
2021
Q3
$21.9M Buy
58,769
+4,591
+8% +$1.74M 0.11% 205
2021
Q2
$20.7M Buy
54,178
+105
+0.2% +$40.1K 0.11% 215
2021
Q1
$19.4M Sell
54,073
-39,664
-42% -$12.8M 0.1% 223
2020
Q4
$30.1M Sell
93,737
-1,292
-1% -$396K 0.17% 154
2020
Q3
$25.5M Sell
95,029
-1,152
-1% -$310K 0.15% 161
2020
Q2
$25.3M Sell
96,181
-62,846
-40% -$16.8M 0.15% 153
2020
Q1
$48M Hold
159,027
0.22% 129
2019
Q4
$48M Sell
159,027
-25,954
-14% -$7.14M 0.22% 129
2019
Q3
$44.4M Sell
184,981
-20,266
-10% -$5.55M 0.2% 133
2019
Q2
$57.9M Sell
205,247
-3,639
-2% -$994K 0.25% 108
2019
Q1
$59.9M Sell
208,886
-6,151
-3% -$1.78M 0.27% 98
2018
Q4
$56.5M Sell
215,037
-8,494
-4% -$2.34M 0.28% 96
2018
Q3
$61.3M Sell
223,531
-27,311
-11% -$7.09M 0.25% 103
2018
Q2
$59.7M Buy
250,842
+65
+0% +$15.1K 0.26% 95
2018
Q1
$56.4M Hold
250,777
0.24% 109
2017
Q4
$56.4M Sell
250,777
-7,855
-3% -$1.67M 0.24% 109
2017
Q3
$49.1M Sell
258,632
-104,648
-29% -$19.9M 0.22% 135
2017
Q2
$60.1M Hold
363,280
0.29% 89
2017
Q1
$60.1M Buy
363,280
+110,985
+44% +$17.7M 0.29% 89
2016
Q4
$36.3M Buy
252,295
+1,112
+0.4% +$149K 0.2% 173
2016
Q3
$31.5M Buy
251,183
+89,095
+55% +$11.5M 0.18% 194
2016
Q2
$21.3M Buy
162,088
+18,056
+13% +$2.47M 0.13% 266
2016
Q1
$20M Sell
144,032
-77,011
-35% -$10.3M 0.13% 259
2015
Q4
$30.8M Sell
221,043
-13,684
-6% -$1.89M 0.21% 140
2015
Q3
$32.9M Buy
234,727
+48,159
+26% +$7.24M 0.24% 117
2015
Q2
$30.6M Sell
186,568
-9,524
-5% -$1.52M 0.22% 137
2015
Q1
$30.3M Sell
196,092
-46,164
-19% -$6.57M 0.22% 127
2014
Q4
$30.4M Buy
242,256
+29,600
+14% +$3.66M 0.24% 118
2014
Q3
$25.4M Buy
212,656
+3,448
+2% +$395K 0.22% 113
2014
Q2
$22.5M Buy
209,208
+23,342
+13% +$2.41M 0.2% 126
2014
Q1
$18.5M Buy
185,866
+32,182
+21% +$2.91M 0.17% 153
2013
Q4
$14.2M Buy
153,684
+17,701
+13% +$1.57M 0.15% 183
2013
Q3
$11.4M Buy
135,983
+5,994
+5% +$514K 0.14% 193
2013
Q2
$10.6M Buy
+129,989
New +$9.73M 0.13% 161

Other funds holding ELV

Glenmede Trust's ELV Position: Q2 2026 in Review

Glenmede Trust increased its Elevance Health (ELV) stake by 3.6% in Q2 2026, buying an estimated $613K and bringing the position to 48,182 shares worth $18.6M. The position accounts for 0.08% of the portfolio, ranked #208.

Glenmede Trust first reported a position in ELV in Q2 2013 and has held it in 51 quarters since. The position peaked at $75.3M in Q4 2023. 1,602 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Glenmede Trust held 48,182 shares of Elevance Health worth $18.6M as of Q2 2026.
  • Glenmede Trust bought 1,654 Elevance Health shares in Q2 2026, an estimated $613K.
  • Elevance Health made up 0.08% of Glenmede Trust's portfolio in Q2 2026, its #208 holding.
  • Glenmede Trust first reported a position in Elevance Health in Q2 2013 and has held it in 51 quarters since.
  • Glenmede Trust's Elevance Health position peaked at $75.3M in Q4 2023.
  • 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.